News & Updates
Filter by Specialty:
Severe COVID-19 rare in PrEP-treated SARDs patients
Breakthrough COVID-19 is not uncommon following pre-exposure prophylaxis (PrEP) with tixagevimab/cilgavimab among patients with systemic autoimmune rheumatic diseases (SARDs), reports a recent study. However, most of the infections in this high-risk population are not severe.
Severe COVID-19 rare in PrEP-treated SARDs patients
08 Mar 2024
Pulse vs nonpulse corticosteroid: Which is better against IPF?
Patients with acute exacerbation of idiopathic pulmonary fibrosis (AE-IPF) who received a pulse dose of corticosteroids do not appear to have longer survival than those who received conventional nonpulse dose of corticosteroids, results of a study have shown.
Pulse vs nonpulse corticosteroid: Which is better against IPF?
07 Mar 2024
Needle-free epinephrine an alternative for anaphylaxis?
In a study presented at AAAAI 2024, epinephrine in preservative-free, nasal powder formulations demonstrated superior stability and comparable plasma exposure to the EpiPen® autoinjector, thus providing a less-invasive treatment option for severe allergic reactions including anaphylaxis.
